论文部分内容阅读
异基因造血干细胞移植(Allo-HSCT)是目前治疗恶性血液病的有效方法,致力于提高植入率和无病存活率,降低移植相关毒性及移植相关病死率,其预处理方案的优化设计是造血干细胞移植的重点。现将我院应用改良BU/CY预处理方案治疗恶性血液病的临床及长期观察情况报道如下。1资料与方
Allo-HSCT is an effective method for the treatment of hematologic malignancies. The aim is to improve the rate of implantation and disease-free survival, and to reduce the graft-related toxicity and transplant-related mortality. The optimal design of the pretreatment scheme is Hematopoietic stem cell transplantation focus. Now our hospital application of modified BU / CY pretreatment program for the treatment of hematological malignancies clinical and long-term observations are reported below. 1 data and party